Findings

What do systematic reviews say?

4,703 questions · 15,007 findings · 1,416 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Sclerotherapy vs placebo

Pain ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Sclerotherapy vs placebo

Recurrence · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy vs placebo

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy vs placebo

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment

BMD: % change in BMD at the lumbar spine · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

1 finding from 1 review

Bisphosphonate use in children with cerebral palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment

Change in volumetric BMD of distal radius or tibia · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

1 finding from 1 review

Bisphosphonate use in children with cerebral palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment

Change in fracture frequency · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

1 finding from 1 review

Bisphosphonate use in children with cerebral palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment

Number of participants reporting an adverse event · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

1 finding from 1 review

Bisphosphonate use in children with cerebral palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
GRADE not reported

Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment

Change in NTX (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

1 finding from 1 review

Bisphosphonate use in children with cerebral palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 32 participants
Very low

Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment

Change in BAP (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)

1 finding from 1 review

Bisphosphonate use in children with cerebral palsy 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 32 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

Participant perception of change with treatment · adult men with premature ejaculation

SSRI probably leads to higher participant perception of change with treatment compared with placebo (moderate certainty).

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
RR 1.92 [1.66, 2.23]
6 studies · 3260 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Participant satisfaction with intercourse · adult men with premature ejaculation

SSRI probably leads to higher participant satisfaction with intercourse compared with placebo (moderate certainty).

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
RR 1.63 [1.42, 1.87]
3 studies · 4273 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Withdrawals due to adverse events · adult men with premature ejaculation

SSRI may leads to higher study withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
RR 3.8 [2.61, 5.51]
20 studies · 7367 participants
Low

Selective serotonin reuptake inhibitors vs placebo

Perceived control over ejaculation · adult men with premature ejaculation

SSRI probably leads to higher perceived control over ejaculation compared with placebo (moderate certainty).

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
RR 2.29 [1.72, 3.05]
3 studies · 4273 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Participant distress about PE · adult men with premature ejaculation

SSRI probably leads to higher participant distress about PE compared with placebo (moderate certainty).

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
RR 1.54 [1.26, 1.88]
1 study · 652 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Adverse events · adult men with premature ejaculation

SSRI probably leads to higher adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
RR 1.71 [1.48, 1.99]
17 studies · 4624 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

IELT · adult men with premature ejaculation

1 finding from 1 review

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
no estimate extracted
20 studies · 5872 participants
Low

Cannabinoids vs placebo

Cognitive function · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity

1 finding from 1 review

Cannabinoids for the treatment of dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Very low

Cannabinoids vs placebo

Behavioural and psychological symptoms of dementia (BPSD) · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity

1 finding from 1 review

Cannabinoids for the treatment of dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 111 participants
Low

Agitated or aggressive behaviours in dementia patients, measured on the Cohen‐Mansfield Agitation Inventory (CMAI) Scale (range 29 to 203, with 29 meaning no symptoms, and higher number of points indicating more severe symptoms)Â · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity

1 finding from 1 review

Cannabinoids for the treatment of dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 100 participants
Low